登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06497530,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Histologically or cytologically confirmed diagnosis of extensive-stage small cell lung cancer (ES-SCLC) and has not received any systemic treatment for ES-SCLC;
入选标准第 4 条
Women of childbearing potential(WOCBP) must have a negative serum pregnancy test before enrollment. WOCBP must use effective contraceptive measure during the trial drug treatment and for 6 months after the last administration. Male patients (with partners of WOCBP) must use effective contraceptive measure during the trial drug treatment and for 4 months after the last administration;
入选标准第 14 条
Have a continuous response or stable disease according to RECIST 1.1 criteria after 4 cycles of induction therapy;
入选标准第 16 条
Toxicity from the induction therapy phase has recovered to ≤ Grade 1;
入选标准第 17 条
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1;
入选标准第 3 条
Platelet count (PLT) ≥ 100×10\^9/L; Hemoglobin (Hb) ≥ 90 g/L; Absolute neutrophil count (ANC) ≥ 2.0×10\^9/L;
入选标准第 7 条
Regardless of whether liver metastasis is present, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3.0×upper limit of normal (ULN);
入选标准第 8 条
Alkaline phosphatase (ALP) ≤ 5×ULN;
入选标准第 9 条
Total bilirubin (TBIL) ≤ 1.5×ULN, and direct bilirubin ≤ 1.0×ULN;
入选标准第 10 条
Serum creatinine ≤ 1.5×ULN or creatinine clearance rate ≥ 30 mL/min (calculated using the Cockcroft-Gault formula);
入选标准第 11 条
Creatine phosphokinase (CPK) ≤ 2.5×ULN;
入选标准第 12 条
At least one measurable lesion (according to RECIST 1.1 criteria);
入选标准第 5 条
Have a history of malignancies other than SCLC within 5 years before enrollment;
排除标准第 3 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06497530,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Fully informed about the study and voluntarily signed a written informed consent form, and able to comply with the requirements and restrictions listed in the informed consent form; Male or female with age ≥ 18 years; Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1; Histologically or cytologically confirmed diagnosis of extensive-stage small cell lung cancer (ES-SCLC) and has not received any systemic treatment for ES-SCLC; At least one measurable lesion (according to RECIST 1.1 criteria); Having adequate bone marrow, hepatic, renal and metabolic function, meaning the functional level of the organs meets the following requirements: Platelet count (PLT) ≥ 100×10\^9/L; Hemoglobin (Hb) ≥ 90 g/L; Absolute neutrophil count (ANC) ≥ 2.0×10\^9/L; Regardless of whether liver metastasis is present, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3.0×upper limit of normal (ULN); Alkaline phosphatase (ALP) ≤ 5×ULN; Total bilirubin (TBIL) ≤ 1.5×ULN, and direct bilirubin ≤ 1.0×ULN; Serum creatinine ≤ 1.5×ULN or creatinine clearance rate ≥ 30 mL/min (calculated using the Cockcroft-Gault formula); Creatine phosphokinase (CPK) ≤ 2.5×ULN; Albumin ≥ 3.0 g/dL. Women of childbearing potential(WOCBP) must have a negative serum pregnancy test before enrollment. WOCBP must use effective contraceptive measure during the trial drug treatment and for 6 months after the last administration. Male patients (with partners of WOCBP) must use effective contraceptive measure during the trial drug treatment and for 4 months after the last administration; Human immunodeficiency virus (HIV)-negative, with no active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Have a continuous response or stable disease according to RECIST 1.1 criteria after 4 cycles of induction therapy; Toxicity from the induction therapy phase has recovered to ≤ Grade 1; Have sufficient bone marrow and organ function.排除标准:Exclusion Criteria:
Have a history of central nervous system (CNS) metastasis or related history; Have a history of active autoimmune disease or immunodeficiency, or related history; Have a history of malignancies other than SCLC within 5 years before enrollment; Previous treatment with immune checkpoint inhibitors or lurbinectedin; Have a history of idiopathic pulmonary fibrosis or pneumonia, or active pneumonia detected in CT screening; Treatment with any other investigational product within 28 days before enrollment. Have a history of central nervous system (CNS) metastasis or related history; Has received chest consolidation radiotherapy; Severe infection within 2 weeks before enrollment.
引自 ClinicalTrials.gov, NCT06497530, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06497530,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。